Saturday, May 27, 2017 12:43:45 AM
Under U.S. GAAP, testing a long-lived asset (asset group) for impairment is a two-step process:
Step 1 — The entity tests the long-lived asset or asset group for recoverability by comparing the carrying amount of the long-lived asset or asset group with the sum of the undiscounted future cash flows and the eventual disposal of the asset.[color=red][/color] If the carrying amount of the long-lived asset or asset group is determined to be greater than the sum of the undiscounted future cash flows, the entity would need to perform step 2. Step 2 — If the long-lived asset or asset group fails the recoverability test in step 1, the entity must record an impairment expense for the difference between the carrying amount and the fair value of the long-lived asset or asset group.
https://www.iasplus.com/en-us/standards/ifrs-usgaap/impairment-of-assets
This is the language in their 8-k today:
Prior to filing the Form 10-Q the Company requires additional time to fully consider whether there is any potential impairment in relation to certain of its long-lived assets in connection with the completion of the audit of its 2016 financial results and the filing of its 2016 Annual Report on Form 10-K.
Please do not tell me it's about selling a nut, a bolt, a chair and a table!
Recent SINT News
- SINTX AND PRODWAYS AGREE ON CERAMIC SLURRY SUPPLY AND 3D PRINTING AGREEMENT • GlobeNewswire Inc. • 04/29/2024 01:14:20 PM
- SINTX Technologies Announces Pricing of $1.5 Million Public Offering of Common Stock • GlobeNewswire Inc. • 04/03/2024 01:00:00 PM
- SINTX Technologies Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/29/2024 08:00:00 PM
- SINTX Technologies Announces Pricing of $1.3 Million Public Offering of Common Stock • GlobeNewswire Inc. • 03/25/2024 01:00:00 PM
- SINTX Technologies Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/22/2024 12:30:00 PM
- SINTX TECHNOLOGIES ENTERS INTO A SECOND LONG TERM SUPPLY AGREEMENT FOR THE AEROSPACE MARKET • GlobeNewswire Inc. • 02/21/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 02:00:28 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:12:54 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/07/2024 09:42:32 PM
- SINTX Technologies Announces Closing of $4.0 Million Public Offering • GlobeNewswire Inc. • 02/02/2024 07:33:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 11:30:20 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/01/2024 10:14:28 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:22 AM
- SINTX Technologies Announces Pricing of $4.0 Million Public Offering • GlobeNewswire Inc. • 01/31/2024 02:20:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 11:05:14 AM
- SINTX SUBSIDIARY TECHNOLOGY ASSESSMENT & TRANSFER TO DEVELOP 3D PRINTING AND CMCs WITH DEVCOM-ARMY RESEARCH LABORATORY • GlobeNewswire Inc. • 01/30/2024 09:01:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/24/2024 09:16:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 02:05:13 PM
- SINTX TECHNOLOGIES SHARES SELECT PRELIMINARY Q4 2023 AND FULL YEAR 2023 REVENUE UPDATE • GlobeNewswire Inc. • 01/23/2024 02:00:00 PM
- SINTX TECHNOLOGIES SIGNIFICANTLY STRENGTHENS ITS ANTIPATHOGENIC PATENT PORTFOLIO • GlobeNewswire Inc. • 01/04/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 12:10:37 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/28/2023 09:44:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 03:10:10 PM
- SINTX TECHNOLOGIES ENTERS A LONG-TERM SUPPLY AGREEMENT FOR AEROSPACE COMPONENTS • GlobeNewswire Inc. • 11/07/2023 02:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM